Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5
Pharm.D. Kyle C Molina, MPSH Victoria Kennerley, MS Laurel E Beaty, MD Tellen D Bennett, PhD Nichole E Carlson, PhD David A Mayerij, BSN Jennifer L Peers, MS Seth Russell, MD Matthew K Wynia, MD, MHSc Neil R Aggarwal, MD, MPH Adit A Ginde
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.04.396
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author Contributions AAG conceived and obtained funding for the study. KCM, VK LEB, NEC, NRA and AAG designed the study. VK, LEB, and NEC analysed the data. VK, LEB, TDB, NEC, DAM, and SR accessed and verified the data. KCM drafted the original version of the manuscript. All authors
Conflict of Interest Statement The authors report no conflicts of interest.
References
Aggarwal, Beaty, Bennett, Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19 Outpatients During an Omicron BA.1 and BA.1.1-Predominant Phase, International Journal of Infectious Diseases
Aggarwal, Beaty, Bennett, Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients, J Infect Dis
Arora, Kempf, Nehlmeier, Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5, The Lancet Infectious Diseases
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat
Dougan, Azizad, Chen, Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19, medRxiv,
doi:10.1101/2022.03.10.22272100v1Heinze, Schemper, A solution to the problem of separation in logistic regression, Statist Med
Heinze, logistf: Firth's Bias-Reduced Logistic Regression, R package version
Ho, Imai, King, Stuart, MatchIt: Nonparametric Preprocessing for Parametric Causal Inference, Journal of Statistical Software
Hoertel, Boulware, Sánchez-Rico, Burgun, Limosin, Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease, JAMA Network Open
Lim, Tignanelli, Hoertel, Boulware, Usher, Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19, Open Forum Infect Dis
Lin, Hung, Lai, Wang, Chen, The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials, J Med Virol
Mccreary, Kip, Collins, Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era, Open Forum Infectious Diseases
Nguyen, Collins, Spence, Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance, BMC Medical Research Methodology
Puhr, Heinze, Nold, Lusa, Geroldinger, Firth's logistic regression with rare events: accurate effect estimates and predictions?, Stat Med
Razonable, Horo, Hanson, Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch, The Journal of Infectious Diseases
Research, De, FDA updates Sotrovimab emergency use authorization
{ 'indexed': {'date-parts': [[2023, 4, 17]], 'date-time': '2023-04-17T04:44:02Z', 'timestamp': 1681706642977},
'reference-count': 0,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2023, 4, 1]],
'date-time': '2023-04-01T00:00:00Z',
'timestamp': 1680307200000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2023, 4, 12]],
'date-time': '2023-04-12T00:00:00Z',
'timestamp': 1681257600000},
'content-version': 'vor',
'delay-in-days': 11,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'ijidonline.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2023, 4]]},
'DOI': '10.1016/j.ijid.2023.04.396',
'type': 'journal-article',
'created': {'date-parts': [[2023, 4, 16]], 'date-time': '2023-04-16T21:16:19Z', 'timestamp': 1681679779000},
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron '
'Variants including BA.4/BA.5',
'prefix': '10.1016',
'author': [ {'given': 'Kyle C.', 'family': 'Molina', 'sequence': 'first', 'affiliation': []},
{'given': 'Victoria', 'family': 'Kennerley', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-8021-7872',
'authenticated-orcid': False,
'given': 'Laurel E.',
'family': 'Beaty',
'sequence': 'additional',
'affiliation': []},
{'given': 'Tellen D.', 'family': 'Bennett', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nichole E.', 'family': 'Carlson', 'sequence': 'additional', 'affiliation': []},
{'given': 'David A.', 'family': 'MayerIJ', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jennifer L.', 'family': 'Peers', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-2436-1367',
'authenticated-orcid': False,
'given': 'Seth',
'family': 'Russell',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-3307-069X',
'authenticated-orcid': False,
'given': 'Matthew K.',
'family': 'Wynia',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-0922-8824',
'authenticated-orcid': False,
'given': 'Neil R.',
'family': 'Aggarwal',
'sequence': 'additional',
'affiliation': []},
{'given': 'Adit A.', 'family': 'Ginde', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'container-title': 'International Journal of Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971223005258?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1201971223005258?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2023, 4, 16]],
'date-time': '2023-04-16T21:16:20Z',
'timestamp': 1681679780000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1201971223005258'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 4]]},
'references-count': 0,
'alternative-id': ['S1201971223005258'],
'URL': 'http://dx.doi.org/10.1016/j.ijid.2023.04.396',
'relation': {},
'ISSN': ['1201-9712'],
'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'],
'container-title-short': 'International Journal of Infectious Diseases',
'published': {'date-parts': [[2023, 4]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Real-World Evaluation of Bebtelovimab Effectiveness During the Period of '
'COVID-19 Omicron Variants including BA.4/BA.5',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'International Journal of Infectious Diseases',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.ijid.2023.04.396',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2023 The Author(s). Published by Elsevier Ltd on behalf of International '
'Society for Infectious Diseases.',
'name': 'copyright',
'label': 'Copyright'}]}
